Cenicriviroc - Tobira Therapeutics

Drug Profile

Cenicriviroc - Tobira Therapeutics

Alternative Names: Cenicriviroc mesylate; CVC; TAK-652; TBR-652

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institute for Health Research; Takeda
  • Developer Dong-A ST; Imperial College of Science, Technology and Medicine; National Institute for Health Research; Tobira Therapeutics
  • Class Amides; Antifibrotics; Antineoplastics; Antiretrovirals; Imidazoles; Small molecules
  • Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-alcoholic steatohepatitis
  • Phase II HIV-1 infections; Non-alcoholic fatty liver disease; Primary sclerosing cholangitis
  • Preclinical Cholestasis; Diabetic nephropathies; Liver disorders
  • No development reported Cancer; Graft-versus-host disease

Most Recent Events

  • 10 Nov 2017 Tobira Therapeutics completes the phase IIb CENTAUR trial for Non-alcoholic steatohepatitis in Australia, Belgium, France, Germany, Hong Kong, Italy, Moldova, Poland, Spain, USA and United Kingdom (PO) (NCT02217475)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Graft-versus-host-disease(Prevention) in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top